(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 61.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.72%.
Rallybio's earnings in 2026 is -$14,170,000.On average, 5 Wall Street analysts forecast RLYB's earnings for 2026 to be -$3,251,187, with the lowest RLYB earnings forecast at -$3,575,936, and the highest RLYB earnings forecast at -$2,550,468.
In 2027, RLYB is forecast to generate -$2,423,737 in earnings, with the lowest earnings forecast at -$2,328,688 and the highest earnings forecast at -$2,495,023.